Thermo Fisher Scientific announced a $22 million total investment since 2021 to expand its oral solid dose (OSD) development and manufacturing capabilities across its Cincinnati, Ohio, and Bend, Oregon, sites. This strategic expansion aims to provide flexible and innovative solutions for early development challenges faced by biotech and pharmaceutical companies.
The investment includes doubling the Bend site’s existing footprint and continuing a multi-year investment plan in Cincinnati, bolstering the company’s global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) network. These additions will enable enhanced research and development, manufacturing, and testing of OSD drug formulations.
The Cincinnati site gains dedicated flexible R&D space for pre-clinical early development, while the Bend expansion focuses on bench and pilot scale spray drying, hot-melt extrusion, and dry granulation. These capabilities are designed to accelerate pre-clinical oral drug product development and reduce timelines to GMP production of clinical trial materials, building on the company's support for over 125 new drug approvals for clients between 2011 and 2023.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.